New hope for older adults battling aggressive blood cancer
NCT ID NCT02835222
Summary
This study is testing whether adding a new oral drug called selinexor to standard chemotherapy helps older adults with a newly diagnosed, aggressive blood cancer called acute myeloid leukemia (AML). The goal is to see if this combination helps patients live longer and better controls the disease compared to standard chemotherapy alone. The trial is for adults over 18 who have not yet received any treatment for their AML.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNTREATED ADULT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Comprehensive Cancer Center of Wake Forest University
Winston-Salem, North Carolina, 27157, United States
-
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.